Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the investigational drug Onvansertib.

According to the submitted SEC filing, Cardiff Oncology accuses Nerviano Medical Sciences of failing to fulfill its obligations under the license agreement, constituting a breach of contract. The core dispute in this lawsuit centers on the rights and responsibilities related to Onvansertib. This legal action marks a significant divergence between the two parties in their cooperation on the development of Onvansertib. Through this move, Cardiff Oncology seeks legal remedies to protect the rights it enjoys under the license agreement. The course of the incident may affect the future research, development, and commercialization of Onvansertib.